It has been recently shown that increased cell sialylation induced lower response of GC cells to the anti-ErbB2 monocolonal antibody trastuzumab [42] as well as reduced response of ovarian cancer cells to the EGFR TKI gefitinib [43]. The gene discussed is EGFR; the disease is ovarian carcinoma.